Return to Search
EN
Peritoneal cancer, often an advanced and invasive form of cancer that has spread from other primary tumors, presents significant treatment challenges. Many tumors associated with peritoneal carcinomatosis respond poorly to conventional chemotherapy, showing minimal shrinkage. Consequently, the primary focus for many healthcare providers is palliative care, aimed at managing symptoms, alleviating pain, and enhancing the patient's quality of life, given the limited curative options.
Effective management hinges on treating the underlying primary cancer that led to peritoneal carcinomatosis. A specialized treatment approach, widely adopted in many centers, combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). CRS involves the meticulous removal of all visible tumor deposits from the peritoneal lining and affected organs. This is followed by HIPEC, where a specially prepared, heated chemotherapy solution is circulated within the abdominal cavity during the same surgical procedure.
This combined modality has demonstrated significant benefits for patients with ovarian, appendix, and primary peritoneal cancers. Patients with colorectal cancer may experience moderate benefits. However, for gastric, pancreatic, and liver cancers, this approach has not shown significant advantage.
HIPEC, also known as heated intraperitoneal chemotherapy, has become an increasingly utilized method in recent years for treating advanced abdominal cancers. It is performed to prolong life expectancy and improve the quality of life, particularly when systemic intravenous chemotherapy proves insufficient due to extensive peritoneal spread. It's crucial to note that HIPEC is not indicated for cancers that have metastasized to organs outside the abdominal cavity, such as the brain, bones, or lungs.
Peritonecectomy, the surgical removal of the peritoneum, is a key component of cytoreductive surgery. It involves meticulously excising the tumor-laden peritoneal lining and any affected organs to achieve the maximal possible tumor debulking within the abdominal cavity. This comprehensive procedure is often referred to as "cytoreductive surgery with peritonecectomy".
Is there a treatment for peritoneal cancer?
Effective management hinges on treating the underlying primary cancer that led to peritoneal carcinomatosis. A specialized treatment approach, widely adopted in many centers, combines cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). CRS involves the meticulous removal of all visible tumor deposits from the peritoneal lining and affected organs. This is followed by HIPEC, where a specially prepared, heated chemotherapy solution is circulated within the abdominal cavity during the same surgical procedure.
This combined modality has demonstrated significant benefits for patients with ovarian, appendix, and primary peritoneal cancers. Patients with colorectal cancer may experience moderate benefits. However, for gastric, pancreatic, and liver cancers, this approach has not shown significant advantage.
HIPEC, also known as heated intraperitoneal chemotherapy, has become an increasingly utilized method in recent years for treating advanced abdominal cancers. It is performed to prolong life expectancy and improve the quality of life, particularly when systemic intravenous chemotherapy proves insufficient due to extensive peritoneal spread. It's crucial to note that HIPEC is not indicated for cancers that have metastasized to organs outside the abdominal cavity, such as the brain, bones, or lungs.
Peritonecectomy, the surgical removal of the peritoneum, is a key component of cytoreductive surgery. It involves meticulously excising the tumor-laden peritoneal lining and any affected organs to achieve the maximal possible tumor debulking within the abdominal cavity. This comprehensive procedure is often referred to as "cytoreductive surgery with peritonecectomy".